- Home
- ANET vs GILD Comparison
ANET vs GILD Comparison
Compare ANET & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANET | GILD |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.1B | 170.9B |
| IPO Year | 2014 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ANET | GILD |
|---|---|---|
| Price | $136.16 | $151.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 17 |
| Target Price | ★ $173.80 | $142.82 |
| AVG Volume (30 Days) | ★ 8.7M | 7.5M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | ★ 23.32 | N/A |
| EPS | 2.75 | ★ 5.04 |
| Revenue | $9,005,700,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $26.69 | $4.68 |
| Revenue Next Year | $20.44 | $5.81 |
| P/E Ratio | $50.89 | ★ $30.28 |
| Revenue Growth | ★ 28.60 | 9.98 |
| 52 Week Low | $59.43 | $95.30 |
| 52 Week High | $164.94 | $157.29 |
Technical Indicators
Market Signals| Indicator | ANET | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 63.94 |
| Support Level | $132.01 | $147.00 |
| Resistance Level | $148.77 | $156.01 |
| Average True Range (ATR) | 6.52 | 4.27 |
| MACD | -0.35 | 0.01 |
| Stochastic Oscillator | 49.42 | 70.28 |
Price Performance
Historical ComparisonAbout ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that mainly sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-quarters of its sales from North America.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).